Based on the differential expression between Treg and Teff cells, CTLA-4, GITR, and OX40 appear to be potential targets in all three human tumor subtypes for dual activity antibodies with capacity for ADCC of intra-tumoral Treg cells. This evidence concerns the gene CTLA4 and neoplasm.